Anxiety Disorders-Pipeline Review, H1 2016

Anxiety Disorders-Pipeline Review, H1 2016


  • Products Id :- GMDHC7698IDB
  • |
  • Pages: 284
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Anxiety Disorders-Pipeline Review, H1 2016', provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders

The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects

The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Anxiety Disorders Overview 11

Therapeutics Development 12

Pipeline Products for Anxiety Disorders-Overview 12

Pipeline Products for Anxiety Disorders-Comparative Analysis 13

Anxiety Disorders-Therapeutics under Development by Companies 14

Anxiety Disorders-Therapeutics under Investigation by Universities/Institutes 18

Anxiety Disorders-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Anxiety Disorders-Products under Development by Companies 23

Anxiety Disorders-Products under Investigation by Universities/Institutes 28

Anxiety Disorders-Companies Involved in Therapeutics Development 30

AbbVie Inc. 30

Ache Laboratorios Farmaceuticos S/A 31

Adamed Sp. z o.o. 32

Addex Therapeutics Ltd 33

Amorsa Therapeutics Inc. 34

Avineuro Pharmaceuticals, Inc. 35

Azevan Pharmaceuticals, Inc. 36

Bionomics Limited 37

Boehringer Ingelheim GmbH 38

C4X Discovery Holdings PLC 39

Catalyst Pharmaceutical Partners, Inc. 40

Edgemont Pharmaceuticals, LLC 41

Eisai Co., Ltd. 42

Eli Lilly and Company 43

F. Hoffmann-La Roche Ltd. 44

Gabather AB 45

GW Pharmaceuticals Plc 46

HolsboerMaschmeyer NeuroChemie GmbH 47

Humanetics Corporation 48

IntelGenx Corp. 49

Intra-Cellular Therapies, Inc. 50

INVENT Pharmaceuticals, Inc. 51

Marinus Pharmaceuticals, Inc. 52

Merz Pharma GmbH & Co. KgaA 53

MI.TO. Technology S.r.L. 54

Nemus Bioscience, Inc. 55

Neuralstem, Inc. 56

Neurelis, Inc. 57

NeuroNascent, Inc. 58

Newron Pharmaceuticals S.p.A. 59

Nippon Chemiphar Co., Ltd. 60

Novartis AG 61

Omeros Corporation 62

Otsuka Holdings Co., Ltd. 63

Pherin Pharmaceuticals, Inc. 64

Polleo Pharma Limited 65

Protagenic Therapeutics Inc. 66

Suda Ltd 67

Sumitomo Dainippon Pharma Co., Ltd. 68

Synchroneuron Inc. 69

Tonix Pharmaceuticals Holding Corp. 70

Trevena, Inc. 71

TRImaran Pharma, Inc. 72

Turing Pharmaceuticals AG 73

Vanda Pharmaceuticals Inc. 74

Anxiety Disorders-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Target 76

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

18-MC-Drug Profile 87

acamprosate calcium SR-Drug Profile 88

ACH-36-Drug Profile 90

ADN-2013-Drug Profile 91

ADX-71441-Drug Profile 92

ADX-71743-Drug Profile 94

ADX-88178-Drug Profile 95

alprazolam-Drug Profile 97

AM-3506-Drug Profile 98

AVN-0189-Drug Profile 100

AVN-101-Drug Profile 101

AVN-628-Drug Profile 102

BNC-210-Drug Profile 103

brexpiprazole-Drug Profile 105

CPP-115-Drug Profile 108

D-473-Drug Profile 110

Drug for Post-Traumatic Stress Disorders-Drug Profile 111

Drugs to Modulate NPSR for Anxiety Disorder-Drug Profile 112

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders-Drug Profile 113

E-2508-Drug Profile 114

evenamide-Drug Profile 115

fluvoxamine maleate-Drug Profile 116

Gaaba-001-Drug Profile 117

ganaxolone-Drug Profile 118

HL-9001-Drug Profile 120

IC-87201-Drug Profile 121

iloperidone-Drug Profile 122

INV-107-Drug Profile 124

INV-170-Drug Profile 125

ITI-007-Drug Profile 126

ketamine hydrochloride-Drug Profile 128

lorazepam-Drug Profile 129

lorazepam ER-Drug Profile 130

loxapine succinate-Drug Profile 131

LSN-2535717-Drug Profile 132

LY-2607540-Drug Profile 133

mavoglurant-Drug Profile 134

midazolam hydrochloride-Drug Profile 136

MRZ-8676-Drug Profile 137

nabiximols-Drug Profile 138

NB-51R1-Drug Profile 141

NEO-1940-Drug Profile 142

NNI-351-Drug Profile 143

NSI-189-Drug Profile 144

OMS-527-Drug Profile 146

Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders-Drug Profile 148

PH-94B-Drug Profile 149

PT-00114-Drug Profile 151

riluzole-Drug Profile 152

RO-646198-Drug Profile 154

Rycal-Drug Profile 155

S-107-Drug Profile 156

SCT-66-Drug Profile 157

Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders-Drug Profile 158

Small Molecule to Antagonize GPR31 for Anxiety Disorders-Drug Profile 159

Small Molecule to Target GPR151 for CNS Diseases-Drug Profile 160

Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis-Drug Profile 161

Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 162

Small Molecule to Target Oxytocin for Autism and Anxiety Disorders-Drug Profile 163

Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders-Drug Profile 164

Small Molecules for Obsessive-Compulsive Disorder-Drug Profile 165

Small Molecules for Post-Traumatic Stress Disorder-Drug Profile 166

Small Molecules for Post-Traumatic Stress Disorder-Drug Profile 167

Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders-Drug Profile 168

Small Molecules to Activate Translocator Protein for Anxiety-Drug Profile 169

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders-Drug Profile 170

Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder-Drug Profile 172

Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety-Drug Profile 173

Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression-Drug Profile 174

Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders-Drug Profile 175

Small Molecules to Antagonize mGlu2 for Anxiety and Depression-Drug Profile 176

Small Molecules to Antagonize mGluR3 for Anxiety and Depression-Drug Profile 177

Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders-Drug Profile 178

Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder-Drug Profile 179

Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders-Drug Profile 180

Small Molecules to Antagonize TLR-4 for CNS Disorders-Drug Profile 181

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy-Drug Profile 182

Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety-Drug Profile 183

Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder-Drug Profile 184

SRX-246-Drug Profile 185

STX-Drug Profile 187

TNX-102-Drug Profile 188

TPI-136117-Drug Profile 190

TRV-250-Drug Profile 191

UCM-765-Drug Profile 193

URB-694-Drug Profile 194

Vaccine for CNS Disorders-Drug Profile 195

VAD-1-Drug Profile 196

VAD-2-Drug Profile 197

vigabatrin-Drug Profile 198

VU-0431316-Drug Profile 201

VU-0456810-Drug Profile 202

ZL-006-Drug Profile 203

Anxiety Disorders-Recent Pipeline Updates 204

Anxiety Disorders-Dormant Projects 248

Anxiety Disorders-Discontinued Products 263

Anxiety Disorders-Product Development Milestones 269

Featured News & Press Releases 269

Appendix 277

Methodology 277

Coverage 277

Secondary Research 277

Primary Research 277

Expert Panel Validation 277

Contact Us 277

Disclaimer 278

List of Figures

Number of Products under Development for Anxiety Disorders, H1 2016 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H1 2016 19

Number of Products under Development by Companies, H1 2016 20

Number of Products under Investigation by Universities/Institutes, H1 2016 24

Comparative Analysis by Clinical Stage Development, H1 2016 26

Comparative Analysis by Early Stage Products, H1 2016 27

Assessment by Monotherapy Products, H1 2016 81

Number of Products by Top 10 Targets, H1 2016 82

Number of Products by Stage and Top 10 Targets, H1 2016 82

Number of Products by Top 10 Mechanism of Actions, H1 2016 86

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 86

Number of Products by Routes of Administration, H1 2016 89

Number of Products by Stage and Routes of Administration, H1 2016 89

Number of Products by Molecule Types, H1 2016 91

Number of Products by Stage and Molecule Types, H1 2016 91

List of Tables

Number of Products under Development for Anxiety Disorders, H1 2016 18

Number of Products under Development for Anxiety Disorders-Comparative Analysis, H1 2016 19

Number of Products under Development by Companies, H1 2016 20

Number of Products under Development by Companies, H1 2016 (Contd..1) 21

Number of Products under Development by Companies, H1 2016 (Contd..2) 22

Number of Products under Development by Companies, H1 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2016 24

Comparative Analysis by Late Stage Development, H1 2016 25

Comparative Analysis by Clinical Stage Development, H1 2016 26

Comparative Analysis by Early Stage Development, H1 2016 27

Comparative Analysis by Unknown Stage Development, H1 2016 28

Products under Development by Companies, H1 2016 29

Products under Development by Companies, H1 2016 (Contd..1) 30

Products under Development by Companies, H1 2016 (Contd..2) 31

Products under Development by Companies, H1 2016 (Contd..3) 32

Products under Development by Companies, H1 2016 (Contd..4) 33

Products under Investigation by Universities/Institutes, H1 2016 34

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 35

Anxiety Disorders-Pipeline by AbbVie Inc., H1 2016 36

Anxiety Disorders-Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 37

Anxiety Disorders-Pipeline by Adamed Sp. z o.o., H1 2016 38

Anxiety Disorders-Pipeline by Addex Therapeutics Ltd, H1 2016 39

Anxiety Disorders-Pipeline by Amorsa Therapeutics Inc., H1 2016 40

Anxiety Disorders-Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 41

Anxiety Disorders-Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 42

Anxiety Disorders-Pipeline by Bionomics Limited, H1 2016 43

Anxiety Disorders-Pipeline by Boehringer Ingelheim GmbH, H1 2016 44

Anxiety Disorders-Pipeline by C4X Discovery Holdings PLC, H1 2016 45

Anxiety Disorders-Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016 46

Anxiety Disorders-Pipeline by Edgemont Pharmaceuticals, LLC, H1 2016 47

Anxiety Disorders-Pipeline by Eisai Co., Ltd., H1 2016 48

Anxiety Disorders-Pipeline by Eli Lilly and Company, H1 2016 49

Anxiety Disorders-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 50

Anxiety Disorders-Pipeline by Gabather AB, H1 2016 51

Anxiety Disorders-Pipeline by GW Pharmaceuticals Plc, H1 2016 52

Anxiety Disorders-Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016 53

Anxiety Disorders-Pipeline by Humanetics Corporation, H1 2016 54

Anxiety Disorders-Pipeline by IntelGenx Corp., H1 2016 55

Anxiety Disorders-Pipeline by Intra-Cellular Therapies, Inc., H1 2016 56

Anxiety Disorders-Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 57

Anxiety Disorders-Pipeline by Marinus Pharmaceuticals, Inc., H1 2016 58

Anxiety Disorders-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 59

Anxiety Disorders-Pipeline by MI.TO. Technology S.r.L., H1 2016 60

Anxiety Disorders-Pipeline by Nemus Bioscience, Inc., H1 2016 61

Anxiety Disorders-Pipeline by Neuralstem, Inc., H1 2016 62

Anxiety Disorders-Pipeline by Neurelis, Inc., H1 2016 63

Anxiety Disorders-Pipeline by NeuroNascent, Inc., H1 2016 64

Anxiety Disorders-Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 65

Anxiety Disorders-Pipeline by Nippon Chemiphar Co., Ltd., H1 2016 66

Anxiety Disorders-Pipeline by Novartis AG, H1 2016 67

Anxiety Disorders-Pipeline by Omeros Corporation, H1 2016 68

Anxiety Disorders-Pipeline by Otsuka Holdings Co., Ltd., H1 2016 69

Anxiety Disorders-Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 70

Anxiety Disorders-Pipeline by Polleo Pharma Limited, H1 2016 71

Anxiety Disorders-Pipeline by Protagenic Therapeutics Inc., H1 2016 72

Anxiety Disorders-Pipeline by Suda Ltd, H1 2016 73

Anxiety Disorders-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 74

Anxiety Disorders-Pipeline by Synchroneuron Inc., H1 2016 75

Anxiety Disorders-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 76

Anxiety Disorders-Pipeline by Trevena, Inc., H1 2016 77

Anxiety Disorders-Pipeline by TRImaran Pharma, Inc., H1 2016 78

Anxiety Disorders-Pipeline by Turing Pharmaceuticals AG , H1 2016 79

Anxiety Disorders-Pipeline by Vanda Pharmaceuticals Inc., H1 2016 80

Assessment by Monotherapy Products, H1 2016 81

Number of Products by Stage and Target, H1 2016 83

Number of Products by Stage and Mechanism of Action, H1 2016 87

Number of Products by Stage and Route of Administration, H1 2016 90

Number of Products by Stage and Molecule Type, H1 2016 92

Anxiety Disorders Therapeutics-Recent Pipeline Updates, H1 2016 210

Anxiety Disorders-Dormant Projects, H1 2016 254

Anxiety Disorders-Dormant Projects (Contd..1), H1 2016 255

Anxiety Disorders-Dormant Projects (Contd..2), H1 2016 256

Anxiety Disorders-Dormant Projects (Contd..3), H1 2016 257

Anxiety Disorders-Dormant Projects (Contd..4), H1 2016 258

Anxiety Disorders-Dormant Projects (Contd..5), H1 2016 259

Anxiety Disorders-Dormant Projects (Contd..6), H1 2016 260

Anxiety Disorders-Dormant Projects (Contd..7), H1 2016 261

Anxiety Disorders-Dormant Projects (Contd..8), H1 2016 262

Anxiety Disorders-Dormant Projects (Contd..9), H1 2016 263

Anxiety Disorders-Dormant Projects (Contd..10), H1 2016 264

Anxiety Disorders-Dormant Projects (Contd..11), H1 2016 265

Anxiety Disorders-Dormant Projects (Contd..12), H1 2016 266

Anxiety Disorders-Dormant Projects (Contd..13), H1 2016 267

Anxiety Disorders-Dormant Projects (Contd..14), H1 2016 268

Anxiety Disorders-Discontinued Products, H1 2016 269

Anxiety Disorders-Discontinued Products (Contd..1), H1 2016 270

Anxiety Disorders-Discontinued Products (Contd..2), H1 2016 271

Anxiety Disorders-Discontinued Products (Contd..3), H1 2016 272

Anxiety Disorders-Discontinued Products (Contd..4), H1 2016 273

Anxiety Disorders-Discontinued Products (Contd..5), H1 2016 274

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc. Ache Laboratorios Farmaceuticos S/A Adamed Sp. z o.o. Addex Therapeutics Ltd Amorsa Therapeutics Inc. Avineuro Pharmaceuticals, Inc. Azevan Pharmaceuticals, Inc. Bionomics Limited Boehringer Ingelheim GmbH C4X Discovery Holdings PLC Catalyst Pharmaceutical Partners, Inc. Edgemont Pharmaceuticals, LLC Eisai Co., Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gabather AB GW Pharmaceuticals Plc HolsboerMaschmeyer NeuroChemie GmbH Humanetics Corporation IntelGenx Corp. Intra-Cellular Therapies, Inc. INVENT Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc. Merz Pharma GmbH & Co. KgaA MI.TO. Technology S.r.L. Nemus Bioscience, Inc. Neuralstem, Inc. Neurelis, Inc. NeuroNascent, Inc. Newron Pharmaceuticals S.p.A. Nippon Chemiphar Co., Ltd. Novartis AG Omeros Corporation Otsuka Holdings Co., Ltd. Pherin Pharmaceuticals, Inc. Polleo Pharma Limited Protagenic Therapeutics Inc. Suda Ltd Sumitomo Dainippon Pharma Co., Ltd. Synchroneuron Inc. Tonix Pharmaceuticals Holding Corp. Trevena, Inc. TRImaran Pharma, Inc. Turing Pharmaceuticals AG Vanda Pharmaceuticals Inc.

Anxiety Disorders Therapeutic Products under Development, Key Players in Anxiety Disorders Therapeutics, Anxiety Disorders Pipeline Overview, Anxiety Disorders Pipeline, Anxiety Disorders Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com